Autoantibodies against tumor‐associated antigens combined with microRNAs in detecting esophageal squamous cell carcinoma

Abstract

Esophageal carcinoma (EC) is a common malignant disease worldwide, especially in China. There is currently no specific blood test for detecting EC. Autoantibodies against tumor-associated antigens (TAAbs) and microRNAs (miRNAs) are promising markers for cancer diagnosis and this study focuses on combining TAAbs and miRNAs to evaluate the diagnostic value in esophageal squamous cell carcinoma (ESCC). The expression levels of seven TAAbs and five microRNAs in plasmas from 125 patients diagnosed with ESCC and 125 healthy individuals were detected by enzyme-linked immunosorbent assay (ELISA) and reverse transcription quantitative-polymerase chain reaction (RT-qPCR), respectively. The receiver operating characteristic (ROC) analysis was applied to estimate the diagnostic value of these markers for distinguishing ESCC patients from normal individuals. Logistic regression analysis was performed to generate prediction model and calculate the probability of individuals being diagnosed with ESCC. Three panels were established including four TAAbs, three miRNAs, and three TAAbs combined with three miRNAs. The panel consisting of three TAAbs (HCCR, C-myc, and MDM2) and three miRNAs (miR-21, miR-223, and miR-375) attained great diagnostic value for ESCC, with an area under the receiver operating characteristic curve (AUC) of 0.89 (95% CI: 0.85-0.93) with the sensitivity of 69%, the specificity of 90%, the PPV of 83%, the NPV of 79%, and the coincidence rate of 81%. The optimal panel of sixmember markers was able to effectively discriminate the patients with ESCC from normal individuals, especially for early esophageal squamous cell carcinoma. K E Y W O R D Sautoantibodies, diagnosis, esophageal squamous cell carcinoma, microRNAs 1174 | SUN et al.

Screening and Evaluating Novel Autoantibodies Based on Proteomic Chips in Diagnosis of Esophageal Squamous Cell Carcinoma

“…Our study produced consistent results that anti-TP53 could be a biomarker for detection of ESCC, meanwhile, the study also found other ve potential TAAbs (anti-MAGEA1, anti-NFKB1, anti-VCL, anti-MAGEA4, anti-PRKCZ). A study found that a panel of three TAAbs (anti-HCCR, anti-C-myc and anti-MDM2) and three miRNAs (miR-21, miR-223 and miR-375) had a high diagnostic value for ESCC with AUC of 0.89, while too many biomarkers combined in the study may not be conducive to large-scale screening and cause more economic burden for patients [37]. Therefore, the author also discovered three TAAbs (anti-GNA11, anti-ACVR1B and anti-TP53) and constructed a model that the diagnostic value of ESCC was 0.88 [38].…”

MicroRNA-21 as a potential biomarker for detecting esophageal carcinoma in Asian populations: a meta-analysis

“…Despite our best efforts, there are several limitations to the present study: (1) study is based on published articles, and unpublished studies or on-going were not included; (2) the sample size in our meta-analysis was small and more high-quality clinical studies are needed to be carried out for validation; (3) Ten of the studies in this meta-analysis had obvious differences in time or place. However, there may have few overlapping patients between two studies (with obvious differences in specificity and sensitivity) ( Sun et al, 2019 ; Zhang et al, 2018 ), and emails sent to the corresponding authors got no response.…”

Humoral immune response to tumor-associated antigen Ubiquilin 1 (UBQLN1) and its tumor-promoting potential in lung cancer

“…Most of the previous studies showed that combining multiple biomarkers can remarkably improve the diagnostic accuracy and speci city in different cancerous diseases, such as OC, BC, ESCC, gastric cancer (GC) and LC [17,[21][22][23][24][25]. Jiang et al utilized decision tree method to construct a diagnostic panel consist of seven TAAbs (TP53, NPM1, FGFR2, PIK3CA, GNA11, HIST1H3B, and TSC1) with the AUC of 0.897 and sensitivity and speci city of 94.4% and 84.9% [17].…”